Literature DB >> 12687597

Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone.

Praveen Ballabh1, M Simm, J Kumari, C Califano, Z Aghai, G Laborada, C Sison, S Cunningham-Rundles.   

Abstract

The first objective of this study was to evaluate longitudinal changes in respiratory burst activity in circulating neutrophils and monocytes in infants of less than 30 weeks of gestation with respiratory distress syndrome (RDS), and to examine differences in neonates who subsequently developed bronchopulmonary dysplasia (BPD) compared with those neonates who did not. The second objective was to investigate the effects of dexamethasone on respiratory burst activity in neutrophils and monocytes. We measured burst activity on neutrophils and monocytes in fresh heparinized blood in response to E. coli, N-formyl-met-leu-phe (fMLP), and phorbol 12-myristate 13-acetate stimulation on days 3, 7, 14, and 21 of life, before and 2-3 days after initiating a 6-day course of dexamethasone treatment. Infants with RDS participating in the study were followed until discharge, and were classified as non-BPD and either 1) BPD d28, reflecting their oxygen requirement at day of life 28, or 2) BPD 36 weeks, reflecting oxygen dependence at 36 weeks' corrected gestational age. The diagnosis of BPD was supported by radiological changes of BPD. The percentage of activated neutrophils producing a respiratory burst increased in all premature infants with increasing postnatal days during the first 28 days of life, when the physiological stimulus E. coli was used as an activator (P < 0.02). There was no significant difference in respiratory burst activity measured either as percent activation or as mean fluorescence intensity between non-BPD and BPD infants after adjusting for the difference in weight and gestational age between the two groups. The treatment of premature infants with dexamethasone was associated with decreased activation of neutrophils (P < 0.005) when E. coli was used as a stimulus. In conclusion, a significant increase in neutrophil respiratory burst activity occurs during the first month of life in very low birth weight infants. Greater pulmonary damage in BPD cannot be attributed to reduced burst activity in either neutrophils or monocytes. Dexamethasone treatment was associated with decreased neutrophil respiratory burst activity. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12687597     DOI: 10.1002/ppul.10279

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

Review 1.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

2.  Persistence of the bacterial pathogen Granulibacter bethesdensis in chronic granulomatous disease monocytes and macrophages lacking a functional NADPH oxidase.

Authors:  Jessica Chu; Helen H Song; Kol A Zarember; Teresa A Mills; John I Gallin
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

3.  Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity.

Authors:  Hong Lin; Elisa de Stanchina; Xi Kathy Zhou; Feng Hong; Andrew Seidman; Monica Fornier; Wei-Lie Xiao; Edward J Kennelly; Kathleen Wesa; Barrie R Cassileth; Susanna Cunningham-Rundles
Journal:  Cancer Immunol Immunother       Date:  2010-02-06       Impact factor: 6.968

4.  Effect of hexane fraction of leaves of Cinnamomum tamala Linn on macrophage functions.

Authors:  J K Chaurasia; Nidhi Pandey; Yamini Bhushan Tripathi
Journal:  Inflammopharmacology       Date:  2010-01-14       Impact factor: 4.473

5.  Interleukin-10 versus dexamethasone: effects on polymorphonuclear leukocyte functions of the newborn.

Authors:  Brett V Citarella; Veronika Miskolci; Ivana Vancurova; Dennis Davidson
Journal:  Pediatr Res       Date:  2009-04       Impact factor: 3.756

6.  Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study.

Authors:  Kathleen M Wesa; Susanna Cunningham-Rundles; Virginia M Klimek; Emily Vertosick; Marci I Coleton; K Simon Yeung; Hong Lin; Stephen Nimer; Barrie R Cassileth
Journal:  Cancer Immunol Immunother       Date:  2014-10-29       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.